IP Library Granted Patent US 6,881,581
Granted Patent B2
US 6,881,581 · App. 10/346,685 · Granted Apr 19, 2005

High-density lipoprotein assay device and method

Assignee: Cholestech Corporation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,881,581
App. No.
10/346,685
Granted
Apr 19, 2005
Kind
B2
Abstract

An assay device and method for measuring the concentration of HDL-associated cholesterol in a blood-fluid sample are described. The assay design is such that removal of non-HDL lipoproteins from a sample and assay of HDL cholesterol in the sample occur without interruption of the assay. The device also prevents interference by reagents used for the HDL assay with other assays carried out on the same sample.

Claims (36)

1. An assay device for measuring serum cholesterol associated with high-density lipoproteins (HDL) in a blood fluid sample also containing low density lipoproteins (LDL) or very low density lipoproteins (VLDL), the device comprising:

a sample distribution matrix effective to distribute a blood fluid sample from a sample application region within the matrix to one or more sample collection regions within the matrix;

an HDL assay element, in which HDL concentration can be assayed, spaced apart from said sample distribution matrix,

a reagent pad, disposed between said HDL assay element and said sample distribution matrix, and spaced apart from said matrix, said reagent pad containing a reagent effective to selectively remove non-HDL lipoproteins from the fluid sample, and

mounting means effective (a) to maintain said device in a sample-distribution position, wherein said HDL assay element and reagent pad are spaced apart from said matrix, and (b) to transfer said device to a test position, whereby the HDL assay element is placed or maintained in contact with the reagent pad, and the reagent pad is, concurrent with or subsequent to said contact, brought into contact with said matrix.

2. The device of claim 1 , wherein a lower surface of the HDL assay element is attached to an upper surface of the reagent pad.

3. The device of claim 1 , further comprising a cassette body to which said sample distribution matrix is attached.

4. The device of claim 3 , further comprising a reaction bar to which said HDL assay element is attached.

5. The device of claim 4 , wherein said mounting means is effective to attach said reaction bar to said cassette body and to adjust the relative positions of the reaction bar and cassette body between said sample-distribution position and said test position.

6. The device of claim 3 , wherein said cassette body further comprises a well for containing said blood fluid sample and a sieving pad for removing cellular blood components from said blood fluid sample, in fluid communication with said sample application region.

7. The device of claim 4 , further comprising additional assay elements attached to said reaction bar, such that said pads are brought into contact with said sample collection regions when the device is transferred to the testing position.

8. The device of claim 1 , wherein said mounting means is further effective to (c) transfer the device from said test position to a position in which said HDL assay element and reagent pad are spaced apart from said matrix.

9. The device of claim 1 , wherein said reaction bar is optically transparent or includes windows through which said assay elements are visible.

10. The device of claim 1 , wherein said reagent includes a sulfonated polysaccharide.

11. The device of claim 1 , wherein said reagent pad is impregnated with said reagent in a form which is soluble in said fluid sample, and is of a material effective to entrap precipitated non-HDL lipoproteins within the reagent pad.

12. The device of claim 1 , wherein said reagent is immobilized to said reagent pad.

13. The device of claim 1 , wherein said HDL assay element contains reagents which, in the presence of HDL-associated cholesterol, produce a change in the assay element which can be detected optically.

14. The device of claim 1 , wherein said HDL assay element comprises a biosensor.

15. The device of claim 14 , wherein said biosensor is effective to measure production of oxygen or hydrogen peroxide which is dependent on HDL-associated cholesterol concentration within said element.

16. The device of claim 1 , wherein said reagent pad comprises a porous polymeric membrane.

17. The device of claim 15 , wherein said reagent pad is an asymmetric polymeric membrane, having a smaller pored surface and an opposite, larger pored surface.

18. The device of claim 17 , wherein said membrane is oriented such that its smaller pored surface faces the HDL assay element.

19. The device of claim 1 , wherein each of said HDL assay element and said reagent pad is an asymmetric polymeric membrane, and said membranes are laminated such that the smaller pored surface of the reagent pad contacts a larger pored surface of the HDL assay element.

20. A method of measuring serum cholesterol associated with high-density lipoproteins (HDL) in a blood fluid sample also containing low density lipoproteins (LDL) or very low density lipoproteins (VLDL), comprising

(a) contacting the sample with an absorptive sample distribution matrix through which said sample is distributed to one or more sample collection sites;

(b) bringing into contact with such a sample collection site, a first surface of a reagent pad, to which said sample is transferred, containing a reagent effective to selectively remove non-HDL lipoproteins from the fluid sample,

wherein an opposite surface of said reagent pad is in simultaneous contact with an HDL assay element, containing assay reagents effective to produce an indication of HDL cholesterol concentration, such that successive sample volumes proceed from said reagent pad to said HDL assay element, and

(c) determining the level of HDL cholesterol in said sample by detection at said HDL assay element.

21. The method of claim 20 , further comprising the step of breaking said contact between the sample collection site and the first surface of the reagent pad, when a desired amount of sample has been transferred.

22. The method of claim 20 , wherein said reagent pad is impregnated with said reagent in a form which is soluble in said fluid sample, and is of a material effective to entrap precipitated non-HDL lipoproteins within the reagent pad.

23. The method of claim 20 , wherein said reagent effective to selectively remove non-HDL lipoproteins is immobilized to said reagent pad.

24. The method of claim 22 , wherein said reagent pad comprises an asymmetric polymeric membrane, having a smaller pored surface and an opposite, larger pored surface.

25. The method of claim 24 , wherein said membrane is oriented such that its smaller pored surface faces said HDL assay element.

26. The method of claim 20 , wherein said HDL assay element comprises a biosensor.

27. The method of claim 26 , wherein said biosensor is effective to measure production of oxygen or hydrogen peroxide which is dependent on HDL-associated cholesterol concentration within said element.

28. The method of claim 24 , wherein each of said HDL assay element and said reagent pad is an asymmetric polymeric membrane, and said membranes are laminated such that the smaller pored surface of the reagent pad contacts a larger pored surface of the HDL assay element.

Assignments (7)
RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY RECORDED AT REEL 036994, FRAME 0192 AND REEL 037115, FRAME 0498 Recorded Oct 5, 2017
From: HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS COLLATERAL AGENT
To: ALERE CONNECT, LLC; ALERE SAN DIEGO, INC. (FKA BIOSITE INC. OR FKA CHOLESTECH CORP. OR FKA HEMOSENSE INC. OR FKA INVERNESS MEDICAL-BIOSTAR INC. OR FKA ISCHEMIA TECHNOLOGIES, INC. OR FKA TWISTDX, INC.); ALERE SCARBOROUGH, INC. (FKA MATRITECH, INC. FKA ADVANTAGE DIAGNOSTICS CORP. OR FKA BINAX, INC. OR FKA MILANO ACQUISITION CORP.); INNOVACON, INC. (FKA APPLIED BIOTECH, INC. OR FKA AMEDITECH INC.); IONIAN TECHNOLOGIES, LLC (FKA IONIAN TECHNOLOGIES, INC.); QUALITY ASSURED SERVICES INC. (FKA ZYCARE INC.); STANDING STONE, LLC; ESCREEN, INC.
Reel/Frame 044213/0258 →
ASSIGNMENT OF IP SECURITY AGREEMENT, PREVIOUSLY RECORDED AT REEL 036994, FRAME 0192 Recorded Nov 16, 2015
From: GENERAL ELECTRIC CAPITAL CORPORATION, AS RETIRING ADMINISTRATIVE AGENT
To: HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS SUCCESSOR ADMINISTRATIVE AGENT
Reel/Frame 037115/0498 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Oct 29, 2015
From: ALERE CONNECT, LLC; ALERE SAN DIEGO, INC. (FKA BIOSITE INC. OR FKA CHOLESTECH CORP. OR FKA HEMOSENSE INC. OR FKA INVERNESS MEDICAL-BIOSTAR INC. OR FKA ISCHEMIA TECHNOLOGIES, INC. OR FKA TWISTDX, INC.); ALERE SCARBOROUGH, INC. (FKA MATRITECH, INC. FKA ADVANTAGE DIAGNOSTICS CORP. OR FKA BINAX, INC. OR FKA MILANO ACQUISITION CORP.); INNOVACON, INC. (FKA APPLIED BIOTECH, INC. OR FKA AMEDITECH INC.); IONIAN TECHNOLOGIES, LLC (FKA IONIAN TECHNOLOGIES, INC.); QUALITY ASSURED SERVICES INC. (FKA ZYCARE INC.); STANDING STONE, LLC; ESCREEN, INC.
To: GENERAL ELECTRIC CAPITAL CORPORATION, AS COLLATERAL AGENT
Reel/Frame 036994/0192 →
NOTICE OF RELEASE OF SECURITY INTEREST IN PATENTS RECORDED AT REEL 026557 FRAME 0287 Recorded Jun 23, 2015
From: GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT AND COLLATERAL AGENT
To: ADVANTAGE DIAGNOSTICS CORPORATION; ALERE MEDICAL, INC.; ALERE SAN DIEGO, INC.; ALERE SCARBOROUGH, INC.; AMEDITECH INC.; APPLIED BIOTECH, INC.; BINAX, INC.; BIOSITE INCORPORATED; CHOLESTECH CORPORATION; GENECARE MEDICAL GENETICS CENTER, INC.; HEMOSENSE, INC.; INSTANT TECHNOLOGIES, INC.; INVERNESS MEDICAL - BIOSTAR INC.; ISCHEMIA TECHNOLOGIES, INC.; MATRITECH, INC.; MATRIA HEALTHCARE, INC.; ZYCARE, INC.
Reel/Frame 036011/0581 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 11, 2012
From: CHOLESTECH CORPORATION
To: ALERE SAN DIEGO, INC
Reel/Frame 028349/0077 →
SECURITY AGREEMENT Recorded Jul 7, 2011
From: ADVANTAGE DIAGNOSTICS CORPORATION; ALERE MEDICAL INCORPORATED; ALERE SAN DIEGO, INC.; ALERE SCARBOROUGH, INC.; AMEDITECH INC.; APPLIED BIOTECH, INC.; BINAX, INC.; BIOSITE INCORPORATED; CHOLESTECH CORPORATION; GENECARE MEDICAL GENETICS CENTER, INC.; HEMOSENSE, INC.; INSTANT TECHNOLOGIES, INC.; INVERNESS MEDICAL - BIOSTAR INC.; ISCHEMIA TECHNOLOGIES, INC.; MATRITECH, INC.; ZYCARE INC.; MARTIA HEALTHCARE, INC.
To: GENERAL ELECTRIC CAPITAL CORPORATION
Reel/Frame 026557/0287 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 8, 2003
From: JONES, RONALD M.; WORTHY, THOMAS E.; NUGENT, ANTHONY J.
To: CHOLESTECH CORPORATION
Reel/Frame 014038/0203 →
Continuity (2)
Provisional Application 6034992600 · Jan 18, 2002
Related Publication 20030166291A1 · Sep 4, 2003